LFSC vs. SBIO
Compare and contrast key facts about F/m Emerald Life Sciences Innovation ETF (LFSC) and ALPS Medical Breakthroughs ETF (SBIO).
LFSC and SBIO are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. LFSC is an actively managed fund by F/m Investments. It was launched on Oct 30, 2024. SBIO is a passively managed fund by SS&C that tracks the performance of the S-Network Medical Breakthroughs Index. It was launched on Dec 31, 2014.
Performance
LFSC vs. SBIO - Performance Comparison
Loading graphics...
LFSC vs. SBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
LFSC F/m Emerald Life Sciences Innovation ETF | -4.45% | 56.54% | -6.02% |
SBIO ALPS Medical Breakthroughs ETF | 3.20% | 55.07% | -9.41% |
Returns By Period
In the year-to-date period, LFSC achieves a -4.45% return, which is significantly lower than SBIO's 3.20% return.
LFSC
- 1D
- 6.16%
- 1M
- -3.82%
- YTD
- -4.45%
- 6M
- 17.66%
- 1Y
- 55.83%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
SBIO
- 1D
- 0.99%
- 1M
- 3.89%
- YTD
- 3.20%
- 6M
- 36.23%
- 1Y
- 95.78%
- 3Y*
- 26.37%
- 5Y*
- 1.76%
- 10Y*
- 9.75%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
LFSC vs. SBIO - Expense Ratio Comparison
LFSC has a 0.54% expense ratio, which is higher than SBIO's 0.50% expense ratio.
Return for Risk
LFSC vs. SBIO — Risk / Return Rank
LFSC
SBIO
LFSC vs. SBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for F/m Emerald Life Sciences Innovation ETF (LFSC) and ALPS Medical Breakthroughs ETF (SBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LFSC | SBIO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.93 | 2.92 | -1.00 |
Sortino ratioReturn per unit of downside risk | 2.65 | 3.57 | -0.93 |
Omega ratioGain probability vs. loss probability | 1.33 | 1.45 | -0.12 |
Calmar ratioReturn relative to maximum drawdown | 3.20 | 5.66 | -2.46 |
Martin ratioReturn relative to average drawdown | 8.96 | 19.94 | -10.98 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| LFSC | SBIO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.93 | 2.92 | -1.00 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.05 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.29 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.94 | 0.23 | +0.72 |
Correlation
The correlation between LFSC and SBIO is 0.83, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
LFSC vs. SBIO - Dividend Comparison
Neither LFSC nor SBIO has paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LFSC F/m Emerald Life Sciences Innovation ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SBIO ALPS Medical Breakthroughs ETF | 0.00% | 0.00% | 3.55% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% |
Drawdowns
LFSC vs. SBIO - Drawdown Comparison
The maximum LFSC drawdown since its inception was -29.74%, smaller than the maximum SBIO drawdown of -63.06%. Use the drawdown chart below to compare losses from any high point for LFSC and SBIO.
Loading graphics...
Drawdown Indicators
| LFSC | SBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -29.74% | -63.06% | +33.32% |
Max Drawdown (1Y)Largest decline over 1 year | -16.25% | -15.08% | -1.17% |
Max Drawdown (5Y)Largest decline over 5 years | — | -53.67% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.06% | — |
Current DrawdownCurrent decline from peak | -11.08% | -13.79% | +2.71% |
Average DrawdownAverage peak-to-trough decline | -8.25% | -28.70% | +20.45% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.80% | 4.28% | +1.52% |
Volatility
LFSC vs. SBIO - Volatility Comparison
The current volatility for F/m Emerald Life Sciences Innovation ETF (LFSC) is 10.35%, while ALPS Medical Breakthroughs ETF (SBIO) has a volatility of 12.61%. This indicates that LFSC experiences smaller price fluctuations and is considered to be less risky than SBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| LFSC | SBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.35% | 12.61% | -2.26% |
Volatility (6M)Calculated over the trailing 6-month period | 19.97% | 22.09% | -2.12% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.24% | 33.43% | -4.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 29.31% | 33.55% | -4.24% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.31% | 33.34% | -4.03% |